Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915488 | 0.88 | MAPT (0.42) | TGFBR1MAPK14MAPTSMN1; SMN2MEN1 | |
| SCHEMBL20600283 | 0.86 | MAPK14 (0.47) | TGFBR1MAPK14MAPTSMN1; SMN2MEN1 | |
| SCHEMBL20600076 | 0.85 | MAPK14 (0.46) | TGFBR1MAPK14MAPTSMN1; SMN2ADORA2A | |
| SCHEMBL20600413 | 0.83 | SLC16A3 (0.41) | TGFBR1MAPK14MAPTSMN1; SMN2MEN1 | |
| SCHEMBL20600063 | 0.81 | MAPT (0.45) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL22613710 | 0.80 | MAPT (0.45) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL20600304 | 0.79 | NPC1 (0.42) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL20600251 | 0.78 | PTGDR (0.44) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL20600390 | 0.77 | MAPT (0.69) | TGFBR1MAPK14MAPTSMN1; SMN2POLB | |
| SCHEMBL29915313 | 0.73 | MAPT (0.40) | TGFBR1MAPK14MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | GRM5, GRIK5, GRM2 | TGFBR1 2248/4885MAPK14 1054/4885MAPT 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.